Dicot Pharma AB

Dicot Pharma is developing the drug candidate LIB-01, which is expected to be a potency drug to treat erectile dysfunction and premature ejaculation. Duration of action and fewer side effects are main desired properties. Dicot's main strategy is to develop LIB-01 in-house up to and including clinical phase 2a study, and then in partnership with major pharmaceutical companies to finance and further develop LIB-01 into a registered drug for the world market.

Quotes for Dicot Pharma AB

Right Now

+/-
%
Latest
High
Low
Volume
Turnover ()
Time (Latest trade)

Board

CEO

  • Elin Trampe

Chairperson of the Board

  • Eva Sjökvist

Board

  • Fredrik Buch
  • Jan-Eric Österlund
  • Michael Zell
  • Mikael von Euler
  • Per-Göran Gillberg
  • Articles of association

    • News

    Show More

    Analysis

    Videos

    Pressträff Direkt

    Dicot - fas 1-resultat 2024

    Largest Owners

    Name Capital % Votes % Date
    Avanza Pension 9,80 9,80 2025-04-25
    Bertil Lindkvist 7,31 7,31 2025-04-25
    Nordnet Pensionsförsäkring 3,23 3,23 2025-04-25
    Tore Robertsson 3,20 3,20 2025-04-25
    Torsten Söderberg med familj 1,80 1,80 2025-04-25
    Stefan Henriksson 1,08 1,08 2025-04-25
    Klas Göran Strömberg 1,04 1,04 2025-04-25
    Michael Zell 0,92 0,92 2025-04-25
    Christian Lentz 0,84 0,84 2025-04-25
    Swedbank Försäkring 0,80 0,80 2025-04-25

    Annual reports, prospectus etc.